PALM BEACH, Florida, May 23, 2018 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
Themulti-billion dollar cannabis industry is projected to experience 28% CAGR through 2021 en route to nearly $25 billion in annual revenues, according to a study conducted by Cannabis Business Plan. States with large populations
CLS Holdings USA, Inc. (OTCQB: CLSH) BREAKING NEWS: Snipp Interactive Inc. (OTCQB: SNIPF) (TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions, today announced that it has signed an MOU with Cannabis Life Sciences - CLS Holdings USA, Inc. ("CLS"), who is in the process of finalizing its purchase of Oasis Cannabis a "seed to sale" company focusing on Cultivation, Production and Dispensaries. CLS showed interest in the Company's solutions by signing up on its recently launched Cannabis Marketing Resource Center ("CMRC").
In addition Cannabis Life Sciences is the developer of a proprietary patent-pending extraction and conversion methodology that has potential to increase yield and quality of cannabinoid oils extracted from cannabis plants. CLS is in the process of expanding its business strategy to include cultivation, production, and retail dispensaries, and is currently in the process of acquiring Oasis Cannabis, a Las Vegas based vertically integrated cannabis company. To learn more visit https://www.clsholdingsinc.com .
The MOU explores a comprehensive partnership to implement a customer loyalty management platform covering all CLS locations across Snipp's SnippCheck, SnippRewards and SnippLoyalty platforms. Snipp will leverage the accumulated knowledge and deep expertise it's has acquired in designing and launching marketing programs in other highly regulated industries like Pharma, Alcohol and tobacco to help CLS run effective and legally compliant promotion and loyalty programs to meet their marketing objectives.
"We have explored a number of loyalty platforms and after extensive review and consultation with SNIPP have concluded that the SNIPP offering allows us to deploy a system that we can leverage as we grow the CLS platform," said JEFF Binder, CEO of CLS.
"We are energized by the interest received in our CMRC. Clearly, there is a need that is currently unmet in the cannabis industry for marketing solutions that can be leveraged across the industry ecosystem and we hope to be the go to resource that fills that need. CLS is a great example of a forward looking company that intends to run a vertically integrated business that is already thinking through the finer points of their future business and operating model," said Atul Sabharwal, CEO of Snipp.
The goal of the CMRC is to help Cannabis marketers hit the ground running by leveraging our deep expertise and the flexible technology platforms we have engineered for highly-regulated industries, which have unique requirements compared to other consumer-oriented segments. This resource center is designed to help cannabis-related companies launch sophisticated solutions that are also legally compliant, a very important aspect for all firms in the space. Read this and more news for CLS Holdings USA at: http://www.marketnewsupdates.com/news/clsh.html
In the industry developments and happenings in the market this week include:
Canopy Growth Corporation (TSX: WEED.TO) (OTC: TWMJF) recently announced it has entered agreement to acquire outstanding shares of research arm Canopy Health Innovations. "Canopy Health has overachieved in its mandate to create value and [intellectual property] relating to medical cannabis applications. By combining its IP with Canopy's production and advanced manufacturing platform, we aim to advance speed to market of medical cannabis products," said Bruce Linton, chairman and chief executive officer, Canopy Growth, and chairman, Canopy Health. "Bringing CHI fully under the Canopy banner at this time and at this price reflects the value of CHI's existing assets and takes into account the upstream value creation Canopy Growth is uniquely capable of layering on." Canopy Growth has built the world's leading ecosystem of cannabis product development, research and international sales channels, all while serving the largest medical patient base in Canada.
mCig Inc. (OTC: MCIG) announced on Tuesday that its STARTUP Supply Division reached $1.5M in sales during its first year of operations. MCIG's supply division has become the "goto" organization for supplies needed in support of the recreational and medical cannabis movement in Nevada. With a well-developed infrastructure headquartered in Las Vegas, Cannabiz Supply, MCIG's supply division operational entity, recently expanded operations into Southern California and is currently in the planning stages of opening a Colorado operation. The Cannabis market continues to exceed all expectations since in the USA and worldwide. Cannabiz Supply has recently entered into negotiations with two of the largest production empires and anticipates becoming their sole source provider in the upcoming months, further entrenching the operations in this blooming market.
PotNetwork Holding Inc. (OTC: POTN) came to a close up 4.68% on Tuesday with a volume north of 2.6 million. Last week, the company announced over $2 million in sales revenues recorded for the month of April. Compared with the $1,009,900 the company achieved in April of 2017, April 2018's revenues represent a 98% year over year increase. PotNetwork Holdings, Inc.'s wholly owned subsidiary Diamond CBD, Inc. recently revealed that Diamond CBD's Vape Additive, Liquid Gold Vape Juice, Chill Gummies, Tinctures and Biotech Creams, are the brand's most successful products according to the 2018 Investor Relations FAQ, and are being sold in 1000's of retail locations across the United States. According to the PotNetwork Holdings, Inc. 2018 Investor Relations FAQ, Diamond CBD's products are selling best in Texas, California, Florida, Georgia and New York. By virtue of Diamond CBD's success in the 4 most populous states in the country, and with close to 25% of its revenues coming from ecommerce, Diamond CBD emerges as market leader in the U.S. domestic hemp-derived CBD oil market.
INSYS Therapeutics Inc. (NASDAQ: INSY) recently announced that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company's New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. "We appreciate the panelists' perspective and guidance," said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. "Believing that our sublingual delivery technology could contribute significantly to bring value to patients, we will continue to work with the FDA in the coming months to discuss the path forward for our buprenorphine product candidate and to build on the current body of evidence for its efficacy and safety." INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients' quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty four hundred dollars for news coverage of the current press release issued by CLS Holdings USA, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact email: email@example.com Tel. No.: +1(561)325-8757
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All